ACCESS Newswire

Latest News

Moderna has initiated a Phase 1 clinical trial for an experimental vaccine targeting Bundibugyo ebolavirus in Canada. The first participant received the mRNA-1469 vaccine on August 3 at a facility in Truro, Nova Scotia. This development occurs as the virus persists in spreading across multiple provinces within the Democratic Republic of the Congo. The World Health Organization has classified the situation as a public health emergency of international concern.